Published in J Am Soc Nephrol on May 21, 2008
Outcomes of simultaneous pancreas-kidney transplantation in type 2 diabetic recipients. Clin J Am Soc Nephrol (2011) 1.49
Twelve-month pancreas graft function significantly influences survival following simultaneous pancreas-kidney transplantation. Clin J Am Soc Nephrol (2009) 0.99
Limitations and future treatment options in type 2 diabetes with renal impairment. Diabetes Care (2011) 0.86
Diabetic nephropathy - Epidemiology in Asia and the current state of treatment. Indian J Nephrol (2011) 0.83
The role of kidney-pancreas transplantation in diabetic kidney disease. Curr Diab Rep (2010) 0.80
A composite risk model for predicting technical failure in pancreas transplantation. Am J Transplant (2013) 0.78
Impact of Medicare coverage on disparities in access to simultaneous pancreas and kidney transplantation. Am J Transplant (2009) 0.77
Utility in Treating Kidney Failure in End-Stage Liver Disease With Simultaneous Liver-Kidney Transplantation. Transplantation (2017) 0.75
Simultaneous liver-kidney transplantation or liver transplantation alone for patients in need of liver transplantation with renal dysfunction. Curr Opin Organ Transplant (2016) 0.75
Pancreas transplantation in type II diabetes mellitus. World J Transplant (2014) 0.75
Pancreas transplantation: differences in activity between Europe and the United States. Nephrol Dial Transplant (2009) 0.75
The impact of method on kidney graft and patient survival in kidney-pancreas transplantations for type I diabetes mellitus. Int Surg (2015) 0.75
Kidney Transplantation in the Diabetic Patient. J Clin Med (2015) 0.75
Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med (1998) 4.30
Long-term effects of pancreatic transplantation on diabetic neuropathy. Ann Neurol (1997) 2.09
Kidney allograft and patient survival in type I diabetic recipients of cadaveric kidney alone versus simultaneous pancreas kidney transplants: a multivariate analysis of the UNOS database. J Am Soc Nephrol (2003) 1.85
Effects of pancreas transplantation on glomerular structure in insulin-dependent diabetic patients with their own kidneys. Lancet (1993) 1.70
The impact of simultaneous pancreas-kidney transplantation on long-term patient survival. Transplantation (2001) 1.46
Effect of simultaneous pancreas-kidney transplantation on mortality of patients with type-1 diabetes mellitus and end-stage renal failure. Lancet (1999) 1.26
Improvements in diabetic microangiopathy after successful simultaneous pancreas-kidney transplantation: a computer-assisted intravital microscopy study on the conjunctival microcirculation. Transplantation (1999) 1.15
Decreased surgical risks of pancreas transplantation in the modern era. Ann Surg (2000) 1.14
Prevention of kidney graft diabetic nephropathy by pancreas transplantation in man. Diabetes (1985) 1.13
Long-term follow-up of 78 simultaneous pancreas-kidney transplants at a single-center institution in Europe. Transplantation (2004) 1.08
Long-term survival following simultaneous kidney-pancreas transplantation versus kidney transplantation alone in patients with type 1 diabetes mellitus and renal failure. Am J Kidney Dis (2003) 1.07
Diabetic neuropathy after pancreas transplantation: determinants of recovery. Transplantation (1997) 1.05
Long-term survival following kidney transplantation in 100 type I diabetic patients. Transplantation (1989) 1.04
Impact of simultaneous kidney-pancreas transplant and timing of transplant on kidney allograft survival. Am J Transplant (2005) 1.03
Kidney graft and patient survival with and without a simultaneous pancreas utilizing contralateral kidneys from the same donor. Diabetes Care (2006) 0.94
Improvement in autonomic and gastric function following pancreas-kidney versus kidney-alone transplantation and the correlation with quality of life. Transplantation (1994) 0.92
Simultaneous pancreas-kidney transplantation reduces excess mortality in type 1 diabetic patients with end-stage renal disease. Kidney Int (2000) 0.91
Therapeutic controversy: Pancreas transplantation for type I diabetes. J Clin Endocrinol Metab (1998) 0.91
Metabolic characterization of long-term successful pancreas transplants in type I diabetes. J Investig Med (1996) 0.90
Diabetic nephropathy as a model of reversibility of established renal lesions. Curr Opin Nephrol Hypertens (1998) 0.90
Long-term metabolic control with pancreatic transplantation. Transplant Proc (1994) 0.80
Sustained improvement in cardiac function 24 months following pancreas-kidney transplant. Transplant Proc (1998) 0.79
Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med (2011) 6.35
Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med (2007) 5.31
Understanding RAGE, the receptor for advanced glycation end products. J Mol Med (Berl) (2005) 4.96
Intensive Supportive Care plus Immunosuppression in IgA Nephropathy. N Engl J Med (2015) 4.78
Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest (2004) 3.89
Effects of donor pretreatment with dopamine on graft function after kidney transplantation: a randomized controlled trial. JAMA (2009) 3.83
A mechanism converting psychosocial stress into mononuclear cell activation. Proc Natl Acad Sci U S A (2003) 3.82
Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J Exp Med (2002) 3.75
High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation (2008) 3.46
Expanding the evidence base in transplantation: the complementary roles of randomized controlled trials and outcomes research. Transplantation (2008) 3.43
Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med (2007) 3.35
Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nat Med (2012) 3.31
Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant (2004) 3.25
Primary malignant hepatic epithelioid hemangioendothelioma: a comprehensive review of the literature with emphasis on the surgical therapy. Cancer (2006) 3.16
Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J Immunol (2005) 3.05
The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med (2003) 2.94
Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation (2013) 2.55
RAGE signaling sustains inflammation and promotes tumor development. J Exp Med (2008) 2.51
Activation pattern of signal transducers and activators of transcription (STAT) factors in inflammatory bowel diseases. Am J Gastroenterol (2005) 2.45
A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J (2007) 2.44
RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol (2003) 2.43
Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes (2008) 2.41
Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest (2003) 2.40
Multicenter analysis of kidney preservation. Transplantation (2007) 2.39
RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis (2008) 2.33
C3 polymorphisms and allograft outcome in renal transplantation. N Engl J Med (2009) 2.29
Atherogenic dyslipidaemia but not total- and high-molecular weight adiponectin are associated with the prognostic outcome in patients with coronary heart disease. Eur Heart J (2008) 2.26
Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? Nat Rev Cancer (2009) 2.26
Role of toll-like receptors 2 and 4, and the receptor for advanced glycation end products in high-mobility group box 1-induced inflammation in vivo. Shock (2009) 2.26
Pharmacologic cholinesterase inhibition improves survival in experimental sepsis. Crit Care Med (2008) 2.18
A role for the receptor for advanced glycation end products in idiopathic pulmonary fibrosis. Am J Pathol (2008) 2.17
Critical evaluation of the amino acid triplet-epitope matching concept in cadaver kidney transplantation. Transplantation (2004) 2.13
Preparation of the dialysis patient for transplantation. Nephrol Dial Transplant (2002) 2.10
Multicentric evaluation of model for end-stage liver disease-based allocation and survival after liver transplantation in Germany--limitations of the 'sickest first'-concept. Transpl Int (2010) 1.99
Cardiovascular death in kidney recipients treated with renin-angiotensin system blockers. Transplantation (2014) 1.96
Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. J Clin Invest (2004) 1.92
Sustained low efficiency dialysis using a single-pass batch system in acute kidney injury - a randomized interventional trial: the REnal Replacement Therapy Study in Intensive Care Unit PatiEnts. Crit Care (2012) 1.90
The junctional adhesion molecule-C promotes neutrophil transendothelial migration in vitro and in vivo. J Biol Chem (2004) 1.89
IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol Immunother (2008) 1.88
H-Y as a minor histocompatibility antigen in kidney transplantation: a retrospective cohort study. Lancet (2008) 1.85
Regulation of human auto- and alloreactive T cells by indoleamine 2,3-dioxygenase (IDO)-producing dendritic cells: too much ado about IDO? Blood (2004) 1.83
Low but sustained coagulation activation ameliorates glucose-induced podocyte apoptosis: protective effect of factor V Leiden in diabetic nephropathy. Blood (2011) 1.83
Glyoxalase-1 prevents mitochondrial protein modification and enhances lifespan in Caenorhabditis elegans. Aging Cell (2008) 1.81
Renal sympathetic denervation therapy in the real world: results from the Heidelberg registry. Clin Res Cardiol (2013) 1.78
Long-term prospective study of steroid withdrawal in kidney and heart transplant recipients. Am J Transplant (2005) 1.78
Serial peripheral blood perforin and granzyme B gene expression measurements for prediction of acute rejection in kidney graft recipients. Am J Transplant (2003) 1.76
Relationship of adiponectin with markers of systemic inflammation, atherogenic dyslipidemia, and heart failure in patients with coronary heart disease. Clin Chem (2006) 1.75
The effect of donor gender on graft survival. J Am Soc Nephrol (2002) 1.72
RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J Am Soc Nephrol (2009) 1.72
No association of kidney graft loss with human leukocyte antigen antibodies detected exclusively by sensitive Luminex single-antigen testing: a Collaborative Transplant Study report. Transplantation (2011) 1.67
Salinomycin induces apoptosis and overcomes apoptosis resistance in human cancer cells. Biochem Biophys Res Commun (2009) 1.65
RAGE (receptor for advanced glycation end products): a central player in the inflammatory response. Microbes Infect (2004) 1.63
Surgical versus medical treatment of type 2 diabetes mellitus in nonseverely obese patients: a systematic review and meta-analysis. Ann Surg (2015) 1.62
Low plasma adiponectin levels are associated with increased hepatic lipase activity in vivo. Diabetes Care (2005) 1.62
Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells. Biochem Biophys Res Commun (2010) 1.62
Pediatric kidney transplantation: analysis of donor age, HLA match, and posttransplant non-Hodgkin lymphoma: a collaborative transplant study report. Transplantation (2010) 1.60
Hantavirus infection. J Am Soc Nephrol (2005) 1.60
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation (2016) 1.59
Dysregulated cytokine responses during cytomegalovirus infection in renal transplant recipients. Transplantation (2008) 1.55
Monitoring of NFAT-regulated gene expression in the peripheral blood of allograft recipients: a novel perspective toward individually optimized drug doses of cyclosporine A. Transplantation (2004) 1.52
Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases. J Biol Chem (2008) 1.52
Living kidney donor follow-up: state-of-the-art and future directions, conference summary and recommendations. Am J Transplant (2011) 1.51
Effect of cytomegalovirus prophylaxis with immunoglobulin or with antiviral drugs on post-transplant non-Hodgkin lymphoma: a multicentre retrospective analysis. Lancet Oncol (2007) 1.51
Malignancy in renal transplantation. J Am Soc Nephrol (2004) 1.50
Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. Blood (2007) 1.48
Prolongation of long-term kidney graft survival by a simultaneous liver transplant: the liver does it, and the heart does it too. Transplantation (2002) 1.48
Living donor kidney transplantation in crossmatch-positive patients enabled by peritransplant immunoadsorption and anti-CD20 therapy. Transpl Int (2012) 1.47
sRAGE is elevated in septic patients and associated with patients outcome. J Surg Res (2007) 1.47
Urinary proinflammatory cytokine response in renal transplant recipients with polyomavirus BK viruria. Transplantation (2009) 1.47
AGE-modified albumin containing infusion solutions boosts septicaemia and inflammation in experimental peritonitis. J Leukoc Biol (2009) 1.45
Partial cholecystectomy as a safe and viable option in the emergency treatment of complex acute cholecystitis: a case series and review of the literature. Am Surg (2007) 1.45
C. elegans as model for the study of high glucose- mediated life span reduction. Diabetes (2009) 1.45
The Case: Renal failure in a male with Waldenström's macroglobulinemia. Kidney Int (2010) 1.44
Long-term remission of paraprotein-induced immunotactoid glomerulopathy after high-dose therapy and autologous blood stem cell transplantation. Ann Hematol (2007) 1.44
Evidence of left ventricular contractile asynchrony by echocardiographic phase imaging in patients with type 2 diabetes mellitus and without clinically evident heart disease. Am J Cardiol (2006) 1.44
Studying the immunosuppressive role of indoleamine 2,3-dioxygenase: tryptophan metabolites suppress rat allogeneic T-cell responses in vitro and in vivo. Transpl Int (2005) 1.43
Impact of HLA compatibility on lung transplant survival and evidence for an HLA restriction phenomenon: a collaborative transplant study report. Transplantation (2010) 1.42
Switch of immunosuppression from cyclosporine A to everolimus: impact on pulse wave velocity in stable de-novo renal allograft recipients. J Hypertens (2008) 1.42
Feasibility and effectiveness of a new algorithm in preventing hepatic artery thrombosis after liver transplantation. J Gastrointest Surg (2008) 1.41
Ex vivo perfusion with mitomycin C containing solution prolongs heart graft survival in rats. Transplantation (2006) 1.41
Individualized monitoring of nuclear factor of activated T cells-regulated gene expression in FK506-treated kidney transplant recipients. Transplantation (2010) 1.41
Detection of hematogenous tumor cell dissemination predicts tumor relapse in patients undergoing surgical resection of colorectal liver metastases. Ann Surg (2005) 1.41
RAGE in inflammation: a new therapeutic target? Curr Opin Investig Drugs (2006) 1.40
Increased proinflammatory endothelial response to S100A8/A9 after preactivation through advanced glycation end products. Cardiovasc Diabetol (2006) 1.40